We are taking a short break, but we will be back next week. Stay tuned!
|Mr. Christian O. Henry M.B.A.||Pres, CEO & Director||772.45k||N/A||1968|
|Ms. Susan G. Kim||Chief Financial Officer||238.87k||N/A||1977|
|Dr. Denis Zaccarin Ph.D.||Sr. VP of R&D||440.43k||N/A||1965|
|Dr. Stephen Turner||Co-Founder & CTO||N/A||N/A||1968|
|Mr. Mark Van Oene||Chief Operating Officer||N/A||N/A||1973|
|Ms. Michele Farmer||VP & Chief Accounting Officer||N/A||N/A||1979|
|Dr. Jonas Korlach Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Trevin Rard||Head of Investor Relations||N/A||N/A||N/A|
|Brett Atkins J.D., Ph.D.||Gen. Counsel & Corp. Sec.||N/A||N/A||N/A|
|Ms. Kathleen Lynch||Head of Global Gov. Affairs & Corp. Communications||N/A||N/A||N/A|
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform; and a research collaboration with Rady Children's Institute for Genomic Medicine for whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Pacific Biosciences of California, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 5. The pillar scores are Audit: 6; Board: 2; Shareholder Rights: 4; Compensation: 9.